Advertisement

Journal of Autism and Developmental Disorders

, Volume 49, Issue 1, pp 376–382 | Cite as

Brief Report: Maternal Opioid Prescription from Preconception Through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children

  • Eric RubensteinEmail author
  • Jessica C. Young
  • Lisa A. Croen
  • Carolyn DiGuiseppi
  • Nicole F. Dowling
  • Li-Ching Lee
  • Laura Schieve
  • Lisa D. Wiggins
  • Julie Daniels
Brief Report

Abstract

Opioid use during pregnancy is associated with suboptimal pregnancy outcomes. Little is known about child neurodevelopmental outcomes. We examined associations between maternal opioid prescriptions preconception to delivery (peri-pregnancy) and child’s risk of ASD, developmental delay/disorder (DD) with no ASD features, or ASD/DD with autism features in the Study to Explore Early Development, a case-control study of neurodevelopment. Preconception opioid prescription was associated with 2.43 times the odds of ASD [95% confidence interval (CI) 0.99, 6.02] and 2.64 times the odds of ASD/DD with autism features (95% CI 1.10, 6.31) compared to mothers without prescriptions. Odds for ASD and ASD/DD were non-significantly elevated for first trimester prescriptions. Work exploring mechanisms and timing between peri-pregnancy opioid use and child neurodevelopment is needed.

Keywords

Risk factor Opioid ASD Developmental disorder Pregnancy 

Notes

Acknowledgments

The investigators acknowledge the contributions made to this study by project staff and enrolled families. A portion of these data were supplied by the Bureau of Health Statistics and Research—PA Department of Health Harrisburg, PA. The PA Department of Health specifically disclaims responsibility for any analysis interpretations or conclusions. This publication was supported by six cooperative agreements from the Centers for Disease Control and Prevention (CDC): Cooperative Agreement Number U10DD000180, Colorado Department of Public Health; Cooperative Agreement Number U10DD000181, Kaiser Foundation Research Institute (CA); Cooperative Agreement Number U10DD000182, University of Pennsylvania; Cooperative Agreement Number U10DD000183, Johns Hopkins University; Cooperative Agreement Number U10DD000184, University of North Carolina at Chapel Hill; and Cooperative Agreement Number U10DD000498, Michigan State University. Eric Rubenstein was additionally supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number T32HD007489 and U54 HD090256. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or NIH.

Author Contributions

Study concept (Eric Rubenstein), study design and methods (all authors), statistical plan (Eric Rubenstein, Julie Daniels, Jessica Young), statistical analysis (Eric Rubenstein), statistical review and interpretation (all authors), manuscript preparation and/or review (all authors).

Compliance with Ethical Standards

Conflict of interest

There are no conflicts of interest to report Eric Rubenstein had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

Supplementary material

10803_2018_3721_MOESM1_ESM.docx (73 kb)
Supplementary material 1 (DOCX 72 KB)

References

  1. American Psychiatric Association. (2000). Diagnostic and statistcal manual of mental disoders (4). Arlington: American Psychiatric Publishing.Google Scholar
  2. Bourgeron, T. (2015). From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nature Reviews: Neuroscience, 16(9), 551–563.  https://doi.org/10.1038/nrn3992.CrossRefPubMedGoogle Scholar
  3. Broussard, C. S., Rasmussen, S. A., Reefhuis, J., Friedman, J. M., Jann, M. W., Riehle-Colarusso, T., et al. (2011). Maternal treatment with opioid analgesics and risk for birth defects. American Journal of Obstetrics and Gynecology.  https://doi.org/10.1016/j.ajog.2010.12.039.CrossRefPubMedGoogle Scholar
  4. Constantino, J. N. (2011). The quantitative nature of autistic social impairment. Pediatric Research. 69(5 Pt 2), 55R–62R,  https://doi.org/10.1203/PDR.0b013e318212ec6e.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Desai, R. J., Hernandez-Diaz, S., Bateman, B. T., & Huybrechts, K. F. (2014). Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstetrics and Gynecology, 123(5), 997–1002.  https://doi.org/10.1097/AOG.0000000000000208.CrossRefPubMedPubMedCentralGoogle Scholar
  6. DiGuiseppi, C. G., Daniels, J. L., Fallin, D. M., Rosenberg, S. A., Schieve, L. A., Thomas, K. C., et al. (2016). Demographic profile of families and children in the Study to Explore Early Development (SEED): Case–control study of autism spectrum disorder. Disability and Health Journal, 9(3), 544–551.  https://doi.org/10.1016/j.dhjo.2016.01.005.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Epstein, R. A., Bobo, W. V., Martin, P. R., Morrow, J. A., Wang, W., Chandrasekhar, R., et al. (2013). Increasing pregnancy-related use of prescribed opioid analgesics. Annals of Epidemiology, 23(8), 498–503.  https://doi.org/10.1016/j.annepidem.2013.05.017.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Gonzalez-Nunez, V., Jimenez Gonzalez, A., Barreto-Valer, K., & Rodriguez, R. E. (2013). In vivo regulation of the mu opioid receptor: Role of the endogenous opioid agents. Molecular Medicine, 19, 7–17.  https://doi.org/10.2119/molmed.2012.00318.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Kivisto, K., Tupola, S., & Kivitie-Kallio, S. (2015). Prenatally buprenorphine-exposed children: Health to 3 years of age. European Journal of Pediatrics, 174(11), 1525–1533.  https://doi.org/10.1007/s00431-015-2562-0.CrossRefPubMedGoogle Scholar
  10. Kocek, M., Wilcox, R., Crank, C., & Patra, K. (2016). Evaluation of the relationship between opioid exposure in extremely low birth weight infants in the neonatal intensive care unit and neurodevelopmental outcome at 2 years. Early Human Development, 92, 29–32.  https://doi.org/10.1016/j.earlhumdev.2015.11.001.CrossRefPubMedGoogle Scholar
  11. Lind, J. N., Interrante, J. D., Ailes, E. C., Gilboa, S. M., Khan, S., Frey, M. T., et al. (2017). Maternal use of opioids during pregnancy and congenital malformations: A systematic review. Pediatrics.  https://doi.org/10.1542/peds.2016-4131.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Lord, C., Rutter, M., DiLavore, P. C., & Risi, S. (2012). Autism diagnostic observation schedule. Journal of Autism and Developmental Disorders. 30, 205–223CrossRefGoogle Scholar
  13. Lyall, K., Croen, L., Daniels, J., Fallin, M. D., Ladd-Acosta, C., Lee, B. K., et al. (2017). The changing epidemiology of autism spectrum disorders. Annual Review of Public Health, 38, 81–102.  https://doi.org/10.1146/annurev-publhealth-031816-044318.CrossRefPubMedGoogle Scholar
  14. Norgaard, M., Nielsson, M. S., & Heide-Jorgensen, U. (2015). Birth and neonatal outcomes following opioid use in pregnancy: A Danish population-based study. Substance Abuse, 9(Suppl 2), 5–11.  https://doi.org/10.4137/SART.S23547.CrossRefPubMedGoogle Scholar
  15. Nygaard, E., Moe, V., Slinning, K., & Walhovd, K. B. (2015). Longitudinal cognitive development of children born to mothers with opioid and polysubstance use. Pediatric Research, 78(3), 330–335.  https://doi.org/10.1038/pr.2015.95.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Pezalla, E. J., Rosen, D., Erensen, J. G., Haddox, J. D., & Mayne, T. J. (2017). Secular trends in opioid prescribing in the USA. Journal of Pain Research, 10, 383–387.  https://doi.org/10.2147/JPR.S129553.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Reddy, U. M., Davis, J. M., Ren, Z., & Greene, M. F., Opioid Use in Pregnancy, N. A. S., & Childhood Outcomes Workshop Invited (2017). Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: Executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstetrics and Gynecology, 130(1), 10–28.  https://doi.org/10.1097/AOG.0000000000002054. S.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Ross, E. J., Graham, D. L., Money, K. M., & Stanwood, G. D. (2015). Developmental consequences of fetal exposure to drugs: What we know and what we still must learn. Neuropsychopharmacology, 40(1), 61–87.  https://doi.org/10.1038/npp.2014.147.CrossRefPubMedGoogle Scholar
  19. Rutter, M., Bailey, A., & Lord, C. (2003a). SCQ: Social Communication Questionnaire. Los Angeles: Western Psychological Services.Google Scholar
  20. Rutter, M., Le Couteur, A., & Lord, C. (2003b). ADI-R: Autism Diagnostic Interview-Revised.Google Scholar
  21. Sahley, T. L., & Panksepp, J. (1987). Brain opioids and autism: An updated analysis of possible linkages. Journal of Autism and Developmental Disorders, 17(2), 201–216.  https://doi.org/10.1007/BF01495056.CrossRefPubMedGoogle Scholar
  22. Schendel, D. E., Diguiseppi, C., Croen, L. A., Fallin, M. D., Reed, P. L., Schieve, L. A., et al. (2012). The Study to Explore Early Development (SEED): A multisite epidemiologic study of autism by the Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) network. Journal of Autism and Developmental Disorders, 42(10), 2121–2140.  https://doi.org/10.1007/s10803-012-1461-8.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Sundelin Wahlsten, V., & Sarman, I. (2013). Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatrica, 102(5), 544–549.  https://doi.org/10.1111/apa.12210.CrossRefPubMedGoogle Scholar
  24. Vuong, C., Van Uum, S. H., O’Dell, L. E., Lutfy, K., & Friedman, T. C. (2010). The effects of opioids and opioid analogs on animal and human endocrine systems. Endocrine Reviews, 31(1), 98–132.  https://doi.org/10.1210/er.2009-0009.CrossRefPubMedGoogle Scholar
  25. Whiteman, V. E., Salemi, J. L., Mogos, M. F., Cain, M. A., Aliyu, M. H., & Salihu, H. M. (2014). Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy. 2014, 906723,  https://doi.org/10.1155/2014/906723.
  26. Wiggins, L. D., Reynolds, A., Rice, C. E., Moody, E. J., Bernal, P., Blaskey, L., et al. (2015). Using standardized diagnostic instruments to classify children with autism in the study to explore early development. Journal of Autism and Developmental Disorders, 45(5), 1271–1280.  https://doi.org/10.1007/s10803-014-2287-3.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Yazdy, M. M., Mitchell, A. A., Tinker, S. C., Parker, S. E., & Werler, M. M. (2013). Periconceptional use of opioids and the risk of neural tube defects. Obstetrics and Gynecology, 122(4), 838–844.  https://doi.org/10.1097/AOG.0b013e3182a6643c.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Waisman CenterUniversity of Wisconsin-MadisonMadisonUSA
  2. 2.Department of Epidemiology, Gillings School of Global Public HealthUniversity of North Carolina Chapel HillChapel HillUSA
  3. 3.Kaiser Permanente Division of ResearchOaklandUSA
  4. 4.Department of Epidemiology, Colorado School of Public HealthUniversity of Colorado Anschutz Medical Campus School of Public HealthAuroraUSA
  5. 5.National Center on Birth Defects and Developmental DisabilitiesCenters for Disease Control and PreventionAtlantaUSA
  6. 6.Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations